There is increasing evidence that spliceosomal component genes themselves are dysregulated in breast cancer, through mutations in SF3B1 that are also observed in metastatic disease and upregulation of SF3B3 and SRSF1 in particular, which are associated with resistance to endocrine therapy. This evidence concerns the gene SF3B1 and breast cancer.